Anti-EGF receptor therapy

Prostate Cancer and Prostatic Diseases

Volumn 3, Issue 4, 2000, Pages 296-302

  Blackledge, G ^a   Averbuch, S ^a   Kay, A ^a   Barton, J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

EGFR; Hormone resistant; Prostate cancer; ZD1839

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ETOPOSIDE; GEFITINIB; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RALTITREXED; TOPOTECAN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; HORMONE RESISTANCE; HUMAN; METASTASIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RASH; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT; VOMITING;

EID: 0034507505     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500488     Document Type: Article

References (50)

1. Growth factors and cancer
2. Growth factors and cancer
3. Kinase inhibitors in cancer therapy. A look ahead
4. Single-molecule imaging of EGFR signalling on the surface of living cells
5. Epidermal growth factor induces cyclin DI in a human prostate cancer cell line
6. Molecules in focus. EGF receptor
7. The epidermal growth factor receptor and its inhibition in cancer therapy
8. EGF and TGF-alpha are potent chemo-attractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration
9. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
10. Epidermal growth factor (EGF) increases the in vitro invasion, motility, and adhesion interactions of the primary renal carcinoma cell line
11. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth
12. Dysregulated expression of growth factors and their receptors in the development of prostate cancer
13. Epidermal growth factor related peptides and their receptors in human malignancies
14. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas
15. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
16. Epidermal growth factor (EGF) intracystic level is predictive of breast cancer risk in women with gross cystic disease of the breast (GCDB)
17. Molecular staging of operable non-small cell lung cancer (NSCLC)
18. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
19. Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells
20. Cancer statistics
21. Long-term cancer patient survival in the United States
22. Hormone resistance in prostate cancer
23. Treatment of cancer with radiation and drugs
24. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer
25. The management of hormone refractory prostate cancer
26. Chemotherapy for advanced hormone refractory prostate cancer
27. Prospects for the treatment of endocrine-responsive tumours
28. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53, and bcl-2 immunoreactivity
29. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate
30. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor
31. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
32. Autonomous growth of androgen independent human prostatic carcinoma cells: Role of transforming growth factor α
33. Binding of epidermal growth factor by human normal, hypertrophic and carcinomatous prostate
34. Epidermal growth factor receptor and other oncogenes as prognostic markers
35. Endocrine resistance in breast cancer can involve a switch towards EGFR signalling pathways and a gain of sensitivity to an EGFR-selective tyrosine kinase inhibitor, ZD1839
36. Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolines
37. Preclinical studies with the oral epidermal growth factor tyrosine kinase receptor inhibitor (EGFR-TKI), ZD1839 ('Iressa'), demonstrate significant anti-tumour activity
38. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor
39. kip1 inducing G1 arrest and enhancing the antitumor effect of interferon-α
40. Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast
41. TM), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: Final results from a Phase I study
42. A Phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with solid malignant tumours
43. TM), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumour types: Evidence of activity and good tolerability
44. Phase I data of ZD1839, an oral epidermal growth factor receptor tyrosine kinase inhibitor